Effects of cardiac overexpression of the angiotensin II type 2 receptor on remodeling and dysfunction in mice post-myocardial infarction

Hypertension

Volumn 63, Issue 6, 2014, Pages 1251-1259

  Xu, Jiang ^a   Sun, Ying ^a,b   Carretero, Oscar A ^a   Zhu, Liping ^a   Harding, Pamela ^a   Shesely, Edward G ^a   Dai, Xiangguo ^a   Rhaleb, Nour Eddine ^a,c   Peterson, Edward ^a   Yang, Xiao Ping ^a,c  

^a HENRY FORD HOSPITAL   (United States)

^b HEBEI UNITED UNIVERSITY   (China)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Mice, transgenic; Myocardial infarction; Receptor, angiotensin, type 1; Receptor, angiotensin, type 2

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MESSENGER RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE DOSAGE; GENE OVEREXPRESSION; HEART; HEART FUNCTION; HEART INFARCTION; HEART RATE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEART WEIGHT; MALE; MOUSE; MUSCLE CELL; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; TRANSGENE; WESTERN BLOTTING;

MICE, TRANSGENIC; MYOCARDIAL INFARCTION; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2;

ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; ANIMALS; BLOOD PRESSURE; BLOTTING, WESTERN; BODY WEIGHT; GENE DOSAGE; GENE EXPRESSION; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, CARDIAC; NADPH OXIDASE; NITRIC OXIDE SYNTHASE TYPE III; ORGAN SIZE; RECEPTOR, ANGIOTENSIN, TYPE 2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR BETA1; VENTRICULAR REMODELING;

EID: 84902295269     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.03247     Document Type: Article

References (32)

1. Utsunomiya H, Nakamura M, Kakudo K, Inagami T, Tamura M. Angiotensin II AT2 receptor localization in cardiovascular tissues by its antibody developed in AT2 gene-deleted mice. Regul Pept. 2005;126:155-161.
2. Wharton J, Morgan K, Rutherford RA, Catravas JD, Chester A, Whitehead BF, De Leval MR, Yacoub MH, Polak JM. Differential distribution of angiotensin AT2 receptors in the normal and failing human heart. J Pharmacol Exp Ther. 1998;284:323-336.
3. Kurisu S, Ozono R, Oshima T, Kambe M, Ishida T, Sugino H, Matsuura H, Chayama K, Teranishi Y, Iba O, Amano K, Matsubara H. Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. Hypertension. 2003;41:99-107.
4. Yayama K, Okamoto H. Angiotensin II-induced vasodilation via type 2 receptor: role of bradykinin and nitric oxide. Int Immunopharmacol. 2008;8:312-318.
5. Zhu L, Carretero OA, Liao TD, Harding P, Li H, Sumners C, Yang XP. Role of prolylcarboxypeptidase in angiotensin II type 2 receptor-mediated bradykinin release in mouse coronary artery endothelial cells. Hypertension. 2010;56:384-390.
6. Xu J, Carretero OA, Zhu L, Shesely EG, Rhaleb NE, Dai X, Wang L, Yang JJ, Yang XP. Protective role of AT(2) and B(1) receptors in kinin B(2)-receptor-knockout mice with myocardial infarction. Clin Sci (Lond). 2013;124:87-96.
7. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest. 1997;99:1926-1935.
8. Xu J, Carretero OA, Liu YH, Shesely EG, Yang F, Kapke A, Yang XP. Role of AT2 receptors in the cardioprotective effect of AT1 antagonists in mice. Hypertension. 2002;40:244-250.
9. Oishi Y, Ozono R, Yoshizumi M, Akishita M, Horiuchi M, Oshima T. AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling. Life Sci. 2006;80:82-88.
10. Falcón BL, Stewart JM, Bourassa E, Katovich MJ, Walter G, Speth RC, Sumners C, Raizada MK. Angiotensin II type 2 receptor gene transfer elicits cardioprotective effects in an angiotensin II infusion rat model of hypertension. Physiol Genomics. 2004;19:255-261.
11. Metcalfe BL, Huentelman MJ, Parilak LD, Taylor DG, Katovich MJ, Knot HJ, Sumners C, Raizada MK. Prevention of cardiac hypertrophy by angiotensin II type-2 receptor gene transfer. Hypertension. 2004;43:1233-1238.
12. Qi Y, Li H, Shenoy V, Li Q, Wang F, Raizada M, Sumners C, Katovich M. Moderate cardiac-selective overexpression of angiotensin type 2 receptor protects cardiac functions from ischemic injury. Exp Physiol. 2011;97:89-101.
13. Yang Z, Bove CM, French BA, Epstein FH, Berr SS, DiMaria JM, Gibson JJ, Carey RM, Kramer CM. Angiotensin II type 2 receptor overexpression preserves left ventricular function after myocardial infarction. Circulation. 2002;106:106-111.
14. Adachi Y, Saito Y, Kishimoto I, et al. Angiotensin II type 2 receptor deficiency exacerbates heart failure and reduces survival after acute myocardial infarction in mice. Circulation. 2003;107:2406-2408.
15. D'Amore A, Black MJ, Thomas WG. The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy. Hypertension. 2005;46:1347-1354.
16. Yan X, Price RL, Nakayama M, Ito K, Schuldt AJ, Manning WJ, Sanbe A, Borg TK, Robbins J, Lorell BH. Ventricular-specific expression of angiotensin II type 2 receptors causes dilated cardiomyopathy and heart failure in transgenic mice. Am J Physiol Heart Circ Physiol. 2003;285:H2179-H2187.
17. Nakayama M, Yan X, Price RL, Borg TK, Ito K, Sanbe A, Robbins J, Lorell BH. Chronic ventricular myocyte-specific overexpression of angiotensin II type 2 receptor results in intrinsic myocyte contractile dysfunction. Am J Physiol Heart Circ Physiol. 2005;288:H317-H327.
18. Xu J, Carretero OA, Lin CX, Cavasin MA, Shesely EG, Yang JJ, Reudelhuber TL, Yang XP. Role of cardiac overexpression of ANG II in the regulation of cardiac function and remodeling postmyocardial infarction. Am J Physiol Heart Circ Physiol. 2007;293:H1900-H1907.
19. Yang XP, Liu YH, Rhaleb NE, Kurihara N, Kim HE, Carretero OA. Echocardiographic assessment of cardiac function in conscious and anesthetized mice. Am J Physiol. 1999;277(5 Pt 2):H1967-H1974.
20. Steckelings UM, Rompe F, Kaschina E, Namsolleck P, Grzesiak A, Funke-Kaiser H, Bader M, Unger T. The past, present and future of angiotensin II type 2 receptor stimulation. J Renin Angiotensin Aldosterone Syst. 2010;11:67-73.
21. Bove CM, Yang Z, Gilson WD, Epstein FH, French BA, Berr SS, Bishop SP, Matsubara H, Carey RM, Kramer CM. Nitric oxide mediates benefits of angiotensin II type 2 receptor overexpression during post-infarct remodeling. Hypertension. 2004;43:680-685.
22. Masaki H, Kurihara T, Yamaki A, Inomata N, Nozawa Y, Mori Y, Murasawa S, Kizima K, Maruyama K, Horiuchi M, Dzau VJ, Takahashi H, Iwasaka T, Inada M, Matsubara H. Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects. J Clin Invest. 1998;101:527-535.
23. Brede M, Roell W, Ritter O, Wiesmann F, Jahns R, Haase A, Fleischmann BK, Hein L. Cardiac hypertrophy is associated with decreased eNOS expression in angiotensin AT2 receptor-deficient mice. Hypertension. 2003;42:1177-1182.
24. Bendall JK, Cave AC, Heymes C, Gall N, Shah AM. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation. 2002;105:293-296.
25. Takata H, Yamada H, Kawahito H, Kishida S, Irie D, Kato T, Wakana N, Miyagawa S, Fukui K, Matsubara H. Vascular angiotensin II type 2 receptor attenuates atherosclerosis via a kinin/NO-dependent mechanism [published online ahead of print June 4, 2013]. J Renin Angiotensin Aldosterone Syst. doi:10.1177/1470320313491794.
26. Iwai M, Chen R, Li Z, Shiuchi T, Suzuki J, Ide A, Tsuda M, Okumura M, Min LJ, Mogi M, Horiuchi M. Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice. Circulation. 2005;112:1636-1643.
27. Chabrashvili T, Kitiyakara C, Blau J, Karber A, Aslam S, Welch WJ, Wilcox CS. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol. 2003;285:R117-R124.
28. Lim H, Zhu YZ. Role of transforming growth factor-beta in the progression of heart failure. Cell Mol Life Sci. 2006;63:2584-2596.
29. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 2004;63:423-432.
30. Hashimoto N, Maeshima Y, Satoh M, Odawara M, Sugiyama H, Kashihara N, Matsubara H, Yamasaki Y, Makino H. Overexpression of angiotensin type 2 receptor ameliorates glomerular injury in a mouse remnant kidney model. Am J Physiol Renal Physiol. 2004;286:F516-F525.
31. 2 receptor stimulation inhibits early renal inflammation in renovascular hypertension. Hypertension. 2011;57:308-313.
32. Habashi JP, Doyle JJ, Holm TM, Aziz H, Schoenhoff F, Bedja D, Chen Y, Modiri AN, Judge DP, Dietz HC. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science. 2011;332:361-365.